Abstract submission is closed!
Abstracts have been submitted .
Thank you for your submissions! Submission was open until 30 May 2022, 23:59 (CET).
We are actively, but not exclusively, seeking abstracts that will complement the following topics. Original research in any area of lymphoid malignancy will also be considered, for platform presentation during our “recent advances” session or for display and discussion in our “poster sessions”.
The lymphoma symposium will be devoted to “Novel frontiers in molecular diagnosis of lymphoma: biomarkers and integrative prognostic models”.
It will explore the plethora of new technologies that help us understand lymphoma biology and are key to pathological classification, and how best to integrate them into our daily clinical practice. The clinical impact of innovative technologies in the management of lymphoma patients will be discussed. In addition, there will be a session on lymphoma entities that are defined by structural chromosomal alterations and the significance of secondary translocations in classification algorithms.
Topics to be reviewed include:
- New horizons in clonality detection
- NGS clonality in routine diagnoses
- The significance of somatic mutations for lymphoma diagnosis and recurrence
- The role of NGS panel sequencing in a routine diagnostic setting will also be explored,
- Algorithms for data evaluation
- Molecular classification of aggressive B-cell, T-cell and low-grade B-cell lymphomas
Abstract submission subject headings
- Clonality analysis and the role of NGS
- NGS panels for diagnosis, including molecular algorithms
- Structural chromosomal alterations in lymphoma
- The clinical impact of innovative technologies in the management of lymphoma patients
- Other topics including recent advances
Bone marrow symposium
The bone marrow symposium will be focused on “Novel frontiers in molecular diagnosis of myeloid neoplasms: biomarkers and integrative prognostic models in myeloid diseases” the aim is to understand how a proper integration of morphological, clinical and molecular data is essential in reaching a correct diagnosis and to guide treatment decision.
Topics to be discussed will include the prognostic and clinical significance of new genetic markers or combinations of genetic markers, the paradigm of targeting oncogenic tyrosine kinase signaling in myeloid neoplasia, and the importance of doing genetic analysis in unusual presentation of myeloid diseases or as marker of disease progression.
Abstracts that will complement these topics will be mainly considered but original studies in any area of myeloid malignancy will also be evaluated for platform presentation or in the “poster sessions”.
Abstract submission subject headings
− myeloid neoplasms with multiple mutations (evolving over time)
− disease categories with molecular markers of disease progression
− NGS panels for diagnosis, including molecular algorithms
Notification of acceptance
The abstracts will be reviewed and selected by the scientific committee. Notifications will be sent to the authors via email no later than two weeks before the closure of the early bird registration for the meeting.
- Abstract text is limited to 3,500 characters (including punctuation and spaces)
- Abstracts must be submitted in English
- Please structure your abstract as follows:
- Title in capital letters and in bold
- Materials and methods
- One table and one graphic can be used
- All abstracts must contain original work
- Please indicate your preferred type of presentation (oral or poster) and choose a topic
- Please check spelling and grammar carefully. All abstracts will be published as submitted
Get the latest updates!
Subscribe to our newsletter to receive the latest news and updates about EAHP-SH! You can unsubscribe from the mailing list at any time.